Abstract Body

We optimized current societal spending on HIV prevention to assess how best to achieve large reductions in HIV incidence.

We used a national model of HIV transmission to estimate the potential maximum 10-year reduction in new infections from 2018 to 2027. The model applied current estimated public and private HIV prevention spending ($2.6 billion for 2018) each year to the following intervention categories: HIV screening (high- and low-risk MSM and heterosexuals, PWID), HIV care continuum (linkage to care at and after diagnosis, prescription of ART, retention in care, viral suppression), PrEP, and SSPs. The model optimized expenditures for two consecutive 5-year periods. We compared the base case (no optimization) to two optimization scenarios: a limited-reach scenario, in which estimates of the maximum number of persons who can be reached by each intervention generally reflect current conditions; and an ideal, unlimited-reach scenario, where all eligible persons can be reached by each intervention.

In the base case in which 30.0% and 16.7% of societal investments are applied to HIV screening and care-continuum interventions, there were 331,000 new cases over the next 10 years. Optimization in the limited-reach scenario in the first 5 years decreased the allocation to HIV screening to 13.4% and increased the allocation to care-continuum interventions to 35.1%. In the unlimited-reach scenario, allocations to both HIV screening and care-continuum interventions increased (to 35.4% and 64.6%, respectively). The 10-year reduction in incidence was 69% in the limited-reach scenario and 94% in the unlimited-reach scenario. Investment in HIV screening decreased in the limited-reach scenario to focus on groups other than low-risk heterosexuals, whereas in the unlimited-reach scenario, screening investments increased to cover all eligible persons. In the unlimited-reach scenario, investment in PrEP was minimized because that scenario included extensive diagnosis and effective viral suppression through the increased funding of ART adherence interventions. However, under the more realistic conditions of the limited-reach scenario, continued investment in PrEP was required.

Optimal allocation of current societal investments in HIV prevention can achieve substantial reductions in new infections. Achieving reductions over 90% is theoretically possible, but implausible with current resources.